Combination therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in heart failure patients with type 2 diabetes [0.03%]
用于2型糖尿病伴心力衰竭患者的钠-葡萄糖共转运体2抑制剂与胰高血糖素样肽1受体激动剂联合治疗
Takefumi Kishimori,Takao Kato,Atsuyuki Wada et al.
Takefumi Kishimori et al.
Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve cardiovascular outcomes in type 2 diabetes (T2D), and SGLT2i reduces events in heart failu...
Observational Study
BMJ open diabetes research & care. 2025 Nov 4;13(6):e005364. DOI:10.1136/bmjdrc-2025-005364 2025
Associations between perceived stress and glycemic measures: gender and age as moderators [0.03%]
感知压力与血糖指标的关系：性别和年龄的调节作用
Ming-Hong Tsai,Charlene Enhui Goh,Michelle H Lee et al.
Ming-Hong Tsai et al.
Introduction: Prediabetes presents an opportunity for early intervention. Growing evidence suggests that psychological stress may contribute to glucose dysregulation, but the findings are inconsistent.This study aimed to ...
Disconnect between advanced diabetes technology and psychological well-being among young people: a cross-sectional analysis [0.03%]
青年糖尿病患者与心理健康的脱节：横断面分析研究
Gundula Ernst,Su-Jong Kim-Dorner,Madelaine Hampel et al.
Gundula Ernst et al.
Introduction: Diabetes technologies may improve glycemic control and psychological well-being among adolescents and young adults (AYA) with type 1 diabetes. This cross-sectional study examines perceptions of automated ins...
Puja Singh,Antonio Garcia,Ellen K Grishman et al.
Puja Singh et al.
Background: Diabetes technology can improve glycemic variability and diabetes outcomes, but there are disparities in patient use. Aims: ...
Sex-specific protective role of lower-body fat in type 2 diabetes: mediation through insulin resistance in a BMI-matched population [0.03%]
BMI匹配人群中下身脂肪的性别保护作用及其通过胰岛素抵抗介导的作用机制研究（队列研究）——中国健康与营养调查
Qiong Wang,Pei-Pei Chen,Wei Wei et al.
Qiong Wang et al.
Introduction: The prevalence of type 2 diabetes (T2D) has surged, yet body mass index (BMI) fails to explain the 30%-40% of cases that occur in individuals with a healthy weight. Emerging evidence suggests that regional f...
Cindy Xinji Cai,Akihiko Nishimura,Sally Baxter et al.
Cindy Xinji Cai et al.
Introduction: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes mellitus (T2D), has potential associations with higher rates of diabetic retinopathy (DR) complications includi...
Observational Study
BMJ open diabetes research & care. 2025 Nov 4;13(6):e005424. DOI:10.1136/bmjdrc-2025-005424 2025
Hemoglobin A1c time-in-range, mortality, and diabetes complications in older adults with diabetes [0.03%]
糖尿病老年人糖化血红蛋白达标时间与死亡和并发症风险的关系
Paul R Conlin,Julia C Prentice,David C Mohr et al.
Paul R Conlin et al.
Introduction: Hemoglobin A1c (A1c) treatment goals in older adults often consider life expectancy and comorbidities. A1c stability may also inform the risks of major outcomes. We studied the association of individualized ...
Observational Study
BMJ open diabetes research & care. 2025 Nov 4;13(6):e005188. DOI:10.1136/bmjdrc-2025-005188 2025
Rapid improvements in glycemic management with use of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin: 3-month analysis of the MOBILE study [0.03%]
连续葡萄糖监测在基础胰岛素治疗的2型糖尿病成人患者中的应用使血糖管理快速改善：MOBILE研究的三个月分析结果
Thomas W Martens,Roy W Beck,Corbin Griffen et al.
Thomas W Martens et al.
Introduction: This analysis investigated whether use of real-time continuous glucose monitoring (CGM) compared with blood glucose monitoring (BGM) results in rapidly improved glycemic management in adults with type 2 diab...
Randomized Controlled Trial
BMJ open diabetes research & care. 2025 Nov 4;13(6):e005469. DOI:10.1136/bmjdrc-2025-005469 2025
Metabolic factors moderate the association between hepatic fibrosis and atherosclerotic cardiovascular risk in type 2 diabetes [0.03%]
代谢因素通过调节2型糖尿病肝纤维化与动脉粥样硬化性心血管疾病风险之间的关系影响CVD发病
Lusi Lu,Chenlu Gao,Nan Wu et al.
Lusi Lu et al.
Introduction: Hepatic fibrosis caused by metabolic dysfunction-associated steatotic liver disease (MASLD) predicts adverse atherosclerotic cardiovascular disease (ASCVD) outcomes in the general patient population. However...
Multicenter Study
BMJ open diabetes research & care. 2025 Nov 4;13(6):e005135. DOI:10.1136/bmjdrc-2025-005135 2025
Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care [0.03%]
利用真实世界数据预测正在进行的IV期试验结果：索马鲁肽与常规护理对照组血糖控制情况的分析
Sushama Kattinakere Sreedhara,Sebastian Schneeweiss,Elvira D&#x;Andrea et al.
Sushama Kattinakere Sreedhara et al.
Objective: Using national claims databases, we sought to emulate the design of the ongoing SEPRA trial and predict its findings, comparing the effects of once weekly semaglutide to SoC medications on glycemic control (A1C